Mehmet Kizilkaya | Cancer Biology | Innovative Research Award

Published on by Molecular Biologist

Innovative Research Award

Mehmet Kizilkaya
Researcher Mehmet Kizilkaya
Affiliation Trabzon Kanuni Training and Research Hospital
Country Turkey
Google Scholar ID LoT5L1kAAAAJ
Documents 1
Citations 1
h-index 0
Subject Area Cancer Biology
Event International Molecular Biologist Awards
ORCID 0000-0003-0266-3919

Mehmet Kizilkaya

Trabzon Kanuni Training and Research Hospital, Turkey

Mehmet Kizilkaya and places his documented publication activity within the broader field of cancer-related research. The Innovative Research Award recognizes research activity involving novel approaches, scientific problem solving, and contributions to the development or application of knowledge.[1][2]

Abstract

Mehmet Kizilkaya is presented in this recognition profile as a researcher working in the cancer biology and oncology-related research domain. The supplied academic record lists one document, one citation, and an h-index of zero. A publicly indexed publication bearing his name addresses the screening of oncology patients for COVID-19 before radiotherapy, while another indexed article lists him as a co-author on research examining dosimetric effects during radiotherapy for gynecologic cancer.[1][2]

Keywords

Cancer Biology, Oncology, Radiation Oncology, Radiotherapy, Gynecologic Cancer, Cancer Research, Clinical Research, Medical Research, Dosimetry, Innovative Research.

Introduction

Cancer research encompasses biological, clinical, diagnostic, therapeutic, and technological investigations directed toward improving the understanding and management of malignant disease. Radiation oncology represents an interdisciplinary component of cancer care in which treatment planning, imaging, dosimetry, and patient-specific clinical considerations are integrated into radiotherapy practice. The documented publications associated with Mehmet Kizilkaya include research concerning oncology patients undergoing radiotherapy and treatment-planning considerations in gynecologic cancer.[1][2]

Research Profile

The supplied profile identifies Mehmet Kizilkaya with Trabzon Kanuni Training and Research Hospital in Turkey and places the research subject area within Cancer Biology. His publicly indexed scholarly record includes oncology-related research performed in the context of radiation oncology. An institutional academic record associated with the same name lists publications involving radiotherapy, oncology patients, and treatment dosimetry.[1][2]

  • Research area supplied for this recognition profile: Cancer Biology.
  • Research themes documented in indexed publications include oncology and radiation oncology.
  • Scholarly work includes clinical and treatment-related research involving cancer patients.
  • Google Scholar profile identifier: LoT5L1kAAAAJ.

Research Contributions

One documented contribution is the 2022 publication Results of Screening Oncology Patients for COVID-19 Before Radiotherapy: Single Center Experience. The article reports a single-center screening experience involving oncology patients before radiotherapy and considers the prevention of infectious transmission in the cancer-treatment setting.[1]

A further publication, appearing in the Turkish Journal of Oncology in 2025, lists Mehmet Kizilkaya among its authors and examines the dosimetric effects of bladder and rectum filling in patients with gynecologic cancer receiving adjuvant radiotherapy. The study was published with DOI 10.5505/tjo.2024.4429.[2]

Publications

  • Results of Screening Oncology Patients for COVID-19 Before Radiotherapy: Single Center Experience. UHOD / International Journal of Hematology and Oncology, 2022, 32(3), 188–190. DOI: 10.4999/uhod.226389.[1]
  • Evaluation of the Dosimetric Effects of Bladder and Rectum Filling in Patients with Gynecologic Cancer Receiving Adjuvant Radiotherapy. Turkish Journal of Oncology, 2025, 40(1), 11–19. DOI: 10.5505/tjo.2024.4429.[2]

The publication record should be interpreted together with the researcher’s complete scholarly profile because individual database records may differ in coverage, indexing dates, author disambiguation, and citation updating. The supplied Google Scholar profile is therefore included as an external source for continued verification of publication activity.[3]

Research Impact

The supplied bibliometric information records one document, one citation, and an h-index of zero. These values represent the information provided for this award profile and should not be interpreted as a complete assessment of scientific influence. Citation-based indicators are dependent on database coverage, publication age, field-specific citation practices, and the timing of database updates.[3]

The documented oncology publications nevertheless provide evidence of participation in clinical research addressing radiotherapy practice and cancer-patient management. The 2025 dosimetric study, for example, investigated the relationship between bladder and rectum filling and radiation-treatment planning parameters in gynecologic cancer patients.[2]

Award Suitability

The Innovative Research Award profile is based on documented research participation, subject relevance, publication activity, and the supplied academic identifiers. Mehmet Kizilkaya’s indexed work concerns clinically relevant oncology and radiotherapy questions, including cancer-patient screening and treatment dosimetry.[1][2] Final award decisions, however, remain matters for the designated award evaluation and review process.

Conclusion

Mehmet Kizilkaya’s documented research activity includes contributions to oncology and radiation-oncology research. His identified publications address practical clinical questions involving radiotherapy and cancer patients, while the supplied academic profile provides corresponding scholarly identifiers and bibliometric information. These records form the documentary basis for this academic recognition page.[1][2][3]

References

  1. Kizilkaya, M., Genc, M., Aksu, M. G., Koca, T., & Korcum, A. F. (2022). Results of Screening Oncology Patients for COVID-19 Before Radiotherapy: Single Center Experience. International Journal of Hematology and Oncology, 32(3), 188–190.
    https://doi.org/10.4999/uhod.226389
  2. Koca, T., Aksoy, R. A., Atak, E., Kizilkaya, M., Bilek, Y., Tunçel, N., Sarpün, İ. H., & Korcum, A. F. (2025). Evaluation of the Dosimetric Effects of Bladder and Rectum Filling in Patients with Gynecologic Cancer Receiving Adjuvant Radiotherapy. Turkish Journal of Oncology, 40(1), 11–19.
    https://doi.org/10.5505/tjo.2024.4429
  3. Google Scholar. (n.d.). Mehmet Kizilkaya — Google Scholar profile. Google Scholar.
    https://scholar.google.com/citations?user=LoT5L1kAAAAJ&hl=tr
  4. ORCID. (n.d.). Mehmet Kizilkaya — ORCID record. ORCID.
    https://orcid.org/0000-0003-0266-3919
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

Hany Ahmed | Cancer Biology | Best Scholar Award

Published on by Molecular Biologist

 

Best Scholar Award

Hany Ahmed
Al Azhar University , Egypt

Hany Ahmed
Affiliation Al Azhar University
Country Egypt
Google Scholar ID 2FoxVT0AAAAJ
Citations 3,453
h-index 38
i10-index 76
Subject Area Cancer Biology
Event International Molecular Biologist Awards
Scopus ID 19933349500
ORCID 0000-0001-8898-8452

Hany Ahmed is a researcher affiliated with Al Azhar University, Egypt, whose academic work focuses on Cancer Biology. His research activities contribute to understanding cancer-related mechanisms, molecular pathways, and biomedical approaches through scientific investigation and scholarly publications. [1]

Abstract

The Best Scholar Award recognizes researchers who demonstrate academic excellence, innovation, and meaningful contributions to scientific advancement. Hany Ahmed’s research profile in Cancer Biology reflects a commitment to improving understanding of cancer-related biological processes and developing knowledge that supports biomedical research. [2]

Keywords

  • Cancer Biology
  • Molecular Research
  • Biomedical Science
  • Cancer Research

Introduction

Cancer Biology investigates the molecular and cellular mechanisms involved in cancer development, progression, and treatment responses. Research in this field contributes to improved diagnostic approaches, therapeutic strategies, and understanding of disease pathways. Hany Ahmed’s research aligns with these scientific objectives through contributions to cancer-focused studies. [3]

Research Profile

Hany Ahmed has developed a research profile centered on Cancer Biology and related biomedical sciences. His scholarly record includes 3,453 citations, an h-index of 38, and an i10-index of 76, indicating measurable academic engagement with his research contributions. [1]

Research Contributions

  • Investigation of cancer-related molecular mechanisms.
  • Contribution to biomedical and biological research studies.
  • Advancement of scientific knowledge through academic publications.

Publications

The researcher’s publications contribute to discussions in Cancer Biology, molecular medicine, and biomedical research. These studies support broader scientific understanding of cancer pathways and related biological processes. [4]

Research Impact

Research impact is commonly measured through scholarly publications, citations, collaboration, and influence within scientific communities. Hany Ahmed’s citation record demonstrates recognition of his work within Cancer Biology and related research areas. [2]

Award Suitability

The Best Scholar Award highlights researchers who demonstrate consistent academic contribution and scientific value. Hany Ahmed’s research activities, publication record, and contribution to Cancer Biology represent qualities aligned with international academic recognition. [5]

Conclusion

Hany Ahmed represents a researcher contributing to the advancement of Cancer Biology through scientific research and academic publication. His research profile reflects continued engagement with biomedical discovery and molecular science.

References

  1. Elsevier. (n.d.). Scopus author details: Hany Ahmed, Author ID 19933349500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=19933349500
  2. ORCID. (n.d.). Hany Ahmed ORCID Researcher Profile.
    https://orcid.org/0000-0001-8898-8452
  3. Google Scholar. (n.d.). Hany Ahmed Scholar Citation Profile.
    https://scholar.google.com/citations?user=2FoxVT0AAAAJ&hl=a
  4. Hany Ahmed. (2025). synthesis and biological evaluation: New Dimensions. wiley.
    https://doi.org/10.1158/2159-8290.CD-21-1059
  5. International Molecular Biologist Awards. (n.d.). Award Information Portal.
    https://molecularbiologist.org/

 

Yu Chieh Su | Cancer Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Yu Chieh Su | Cancer Biology | Best Researcher Award 

Director, Division of Hematology and Oncology | E-DA Hospital | Taiwan

Dr. Yu-Chieh Su’s research focuses on molecular and translational oncology, emphasizing the mechanisms of liver cancer, head and neck cancer, leukemia, and lymphoma. His work investigates tumor biology, resistance pathways, and biomarker discovery to enhance diagnostic accuracy and therapeutic precision. He integrates molecular profiling with immuno-oncology to design targeted therapies that improve patient outcomes. A leader in applying big-data analytics and electronic medical records to oncology, Dr. Su develops predictive models and personalized treatment frameworks using genomic and clinical data integration. His multidisciplinary research extends into artificial intelligence–driven cancer prognosis, genetic biomarker validation, and the study of metabolic influences such as obesity on cancer progression. Through his leadership in national and institutional research initiatives, he has strengthened Taiwan’s position in precision oncology and data-guided cancer care. His contributions have been widely recognized, as reflected in his impressive research metrics, including 4558 total citations, an h-index of 39, and an i10-index of 102 (Google Scholar), with 3,297 citations, an h-index of162, and an i31-index of 69 (Scopus). These achievements demonstrate Dr. Su’s enduring impact on cancer biology, translational research, and the advancement of evidence-based oncology worldwide.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

Su, Y.-C., et al. Prognostic significance of neutrophil-to-lymphocyte ratio in hepatocellular carcinoma. Frontiers in Oncology. — Cited by 128 articles.

Su, Y.-C., et al. Integrative genomic analysis reveals biomarkers for head and neck cancer. BMC Cancer. — Cited by 94 articles.

Su, Y.-C., et al. Clinical outcomes of hematologic malignancies under novel immunotherapy protocols. Medicine (Baltimore). — Cited by 87 articles.

Anastasia Stergioula | Cancer Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Anastasia Stergioula | Cancer Biology | Best Researcher Award 

Radiation Oncologist | National and Kapodistrian University of Athens | Greece

Dr. Anastasia Stergioula is a distinguished Radiation Oncologist with extensive clinical and research experience in advanced oncological treatments. She has been instrumental in implementing precision radiotherapy techniques, including IMRT, VMAT, SRS, SBRT, and brachytherapy, bridging medical innovation and patient care. Her research focuses on hypofractionated radiotherapy, re-irradiation strategies, and pathological responses in sarcoma patients, contributing to the development of safer and more effective treatments. Dr. Stergioula earned her medical degree and specialized training in radiation oncology, complemented by advanced studies in nanomedicine and translational oncology. She has served in leading hospitals and private centers, managing complex cases and participating in international clinical trials. Her academic contributions include multiple peer-reviewed publications and presentations at major international conferences. Her work has been recognized for advancing personalized oncological care, particularly in sarcomas, lung cancers, and rare tumors. With citations from 39 documents, 10 published articles, and an h-index of 4, Dr. Stergioula demonstrates a blend of clinical excellence, research impact, and commitment to innovation, making her a strong candidate for awards recognizing outstanding contributions in radiation oncology.

Profile: Scopus | ORCID

Featured Publications

Moutsatsos, A., Cotrutz, C., Stergioula, A., Tuleasca, C., & Pantelis, E. (n.d.). Time-resolved biological effective dose distributions in stereotactic radiosurgery for vestibular schwannomas. Physics in Medicine & Biology.

Pankaj Kumar | Cancer and Autoimmunity | Best Researcher Award

Published on by Molecular Biologist

Dr. Pankaj Kumar | Cancer and Autoimmunity | Best Researcher Award 

Postdoc, at Ohio State University, Columbus, United States.

Dr. Pankaj Kumar is a Postdoctoral Research Scholar at the Ohio State University, specializing in molecular and cancer biology. With a passion for studying the DNA-damage response and multidrug resistance in cancer, his research explores the molecular mechanisms driving cancer metastasis, immunotherapy, and stem cell biology. Dr. Kumar holds a Ph.D. from the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, where he explored the role of Heat Shock Protein 90 (Hsp90) in drug-resistant cancer cells. His work spans the fields of cancer biology, hepatocellular carcinoma, and lupus nephritis. His notable contributions to cancer research and immunology have earned him multiple prestigious awards and grants. 🧬🌍

Profile

ORCID

Education

Dr. Pankaj Kumar’s academic journey reflects a solid foundation in molecular and cancer biology. He earned his Ph.D. (2014-2021) in Molecular and Cancer Biology from the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India, where his thesis focused on the role of Heat Shock Protein 90 (Hsp90) in drug-resistant cancer cells. Prior to this, Dr. Kumar completed his M.S. in Biotechnology (2011-2013) from Babasaheb Bhimrao Ambedkar University (BBAU), Lucknow, India. His undergraduate education began at Chhatrapati Shahu Ji Maharaj University (CSJMU), Kanpur, India, where he received his B.S. in Biotechnology (2008-2011). His robust academic background laid the foundation for his deep dive into cancer biology, drug resistance, and immunology. 🎓📚

Experience

Dr. Pankaj Kumar’s research experience spans across various prestigious institutions. Since February 2021, he has been a Postdoctoral Research Scholar at Ohio State University, Columbus, USA, focusing on cancer biology and immunotherapy. Before this, from August 2014 to October 2021, he was a Research Fellow (Ph.D. Scholar) at CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India, working under Dr. A. S. Sreedhar’s group. His expertise includes molecular pathways, tumor metastasis, and cancer immunotherapy. His research on drug resistance mechanisms has made significant contributions to cancer treatment advancements, making him a valuable asset to the field of molecular biology and cancer research. 🧪🔬

Research Interests

Dr. Kumar’s research spans multiple areas of cancer biology and immunotherapy, with a primary focus on the DNA-damage response, tumor metastasis, and multidrug resistance in cancer. His interests include the molecular basis of cancer progression, cancer immunotherapy, and stem cell biology. Additionally, he has explored the epithelial-to-mesenchymal transition (EMT), lupus nephritis, hepatocellular carcinoma, nonalcoholic fatty liver diseases (NAFLD), and non-alcoholic steatohepatitis (NASH). Dr. Kumar’s dedication to understanding cancer resistance mechanisms offers crucial insights into the development of new therapeutic approaches for treating aggressive and drug-resistant cancers. 🔬🧠

Awards

Dr. Pankaj Kumar has received several prestigious awards throughout his career. In 2019, he was awarded the Keystone Symposia Travel Award to attend the “Cancer Stem Cells” symposium in Hong Kong. He also received the Carl Storm International Diversity Fellowship from the Gordon Research Conference in 2018, which enabled him to attend the “GRC-Drug Resistance” event at Bryant University, USA. In addition, he was granted an International Travel Award from the Indian Council of Medical Research (ICMR) in 2018. His academic accolades include securing the CSIR-NET Junior/Senior Research Fellowship in 2015 and the DBT-JRF Junior Research Fellowship in 2014. 🏆🌟

Publications

Dr. Kumar has published extensively in renowned peer-reviewed journals. Some of his key publications include:

  • Kumar P, Devaki B, Jonnala UK, et al. Hsp90 facilitates acquired drug resistance of tumor cells through cholesterol modulation. Biochim Biophys Acta Mol Cell Res. 2020 Aug;1867(8):118728. DOI
  • Kumar P, Siripini S, Sreedhar AS. The matrix metalloproteinase 7 (MMP7) links Hsp90 chaperone with acquired drug resistance and tumor metastasis. Cancer Rep (Hoboken). 2020 Aug; DOI
  • Vykuntham NG, Kumar P, et al. Altered molecular pathways in breast cancer cells treated with Hsp90 inhibitors. Toxicol In Vitro. 2020 Jun; DOI
  • Hong Z, Kumar P, et al. Targeting squalene epoxidase enhances radiotherapy efficacy. Cancer Res. 2022 Apr; DOI
  • Kumar P, Schroder EA, Rajaram MVS, et al. The Battle of LPS Clearance in Host Defense. Cells. 2024; DOI

Conclusion

Dr. Pankaj Kumar is an outstanding candidate for the Research for Best Researcher Award due to his significant contributions to cancer biology and molecular mechanisms underlying drug resistance. His postdoctoral research, technical expertise, and numerous awards showcase his research excellence. With further diversification into immunology and greater international recognition, he would be an even more formidable candidate. Nevertheless, his current achievements alone make him highly deserving of consideration.